Dr. Pat Whitworth on the Importance of the Luminal Subtype in Breast Cancer

Video

Whitworth says that while it is generally perceived that the ER-positive/HER2-negative breast cancer patient population is the luminal subtype, 1 of every 5 of those patients would actually considered basal subtype.

Pat Whitworth, MD, breast surgical oncologist, Nashville Breast Center, discusses how the discovery of luminal subtyping in breast cancer changed the paradigm of treatment. Whitworth says that while it is generally perceived that the ER-positive/HER2-negative breast cancer patient population is the luminal subtype, 1 of every 5 of those patients would actually considered basal subtype. Whitworth says the reason this is important, is that the basal subtype normally has a much higher pathological complete response rate than the luminal subtype.

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content